US20100129352A1 - Novel pharmaceutical composition - Google Patents

Novel pharmaceutical composition Download PDF

Info

Publication number
US20100129352A1
US20100129352A1 US12/598,673 US59867307A US2010129352A1 US 20100129352 A1 US20100129352 A1 US 20100129352A1 US 59867307 A US59867307 A US 59867307A US 2010129352 A1 US2010129352 A1 US 2010129352A1
Authority
US
United States
Prior art keywords
diluent
substantially free
pharmaceutical
micron
diluents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/598,673
Other languages
English (en)
Inventor
Francis X. Muller
Shivakumar G. Kapsi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39343460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100129352(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Priority to US12/598,673 priority Critical patent/US20100129352A1/en
Assigned to SMITHKLINE BEECHAM CORPORATION reassignment SMITHKLINE BEECHAM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAPSI, SHIVAKUMAR G., MULLER, FRANCIS X
Assigned to GLAXOSMITHKLINE LLC reassignment GLAXOSMITHKLINE LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SMITHKLINE BEECHAM CORPORATION
Publication of US20100129352A1 publication Critical patent/US20100129352A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
US12/598,673 2007-05-03 2007-08-01 Novel pharmaceutical composition Abandoned US20100129352A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/598,673 US20100129352A1 (en) 2007-05-03 2007-08-01 Novel pharmaceutical composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91576107P 2007-05-03 2007-05-03
US94773107P 2007-07-03 2007-07-03
PCT/US2007/074918 WO2008136843A1 (en) 2007-05-03 2007-08-01 Novel pharmaceutical composition
US12/598,673 US20100129352A1 (en) 2007-05-03 2007-08-01 Novel pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20100129352A1 true US20100129352A1 (en) 2010-05-27

Family

ID=39343460

Family Applications (15)

Application Number Title Priority Date Filing Date
US12/598,673 Abandoned US20100129352A1 (en) 2007-05-03 2007-08-01 Novel pharmaceutical composition
US12/607,320 Active US8062665B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,284 Active US8071129B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,330 Active US8052995B2 (en) 2007-05-03 2009-10-28 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,291 Active US8052993B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,305 Active US8052994B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US13/272,367 Active 2027-09-20 US8828430B2 (en) 2007-05-03 2011-10-13 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US14/450,569 Abandoned US20140341991A1 (en) 2007-05-03 2014-08-04 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US14/851,497 Abandoned US20160031822A1 (en) 2007-05-03 2015-09-11 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/073,708 Abandoned US20160199353A1 (en) 2007-05-03 2016-03-18 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/343,382 Abandoned US20170112771A1 (en) 2007-05-03 2016-11-04 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/638,693 Abandoned US20170296512A1 (en) 2007-05-03 2017-06-30 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/852,090 Abandoned US20180117009A1 (en) 2007-05-03 2017-12-22 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US16/054,451 Abandoned US20180338926A1 (en) 2007-05-03 2018-08-03 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US16/356,498 Abandoned US20190209479A1 (en) 2007-05-03 2019-03-18 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)

Family Applications After (14)

Application Number Title Priority Date Filing Date
US12/607,320 Active US8062665B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,284 Active US8071129B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,330 Active US8052995B2 (en) 2007-05-03 2009-10-28 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,291 Active US8052993B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US12/607,305 Active US8052994B2 (en) 2007-05-03 2009-10-28 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US13/272,367 Active 2027-09-20 US8828430B2 (en) 2007-05-03 2011-10-13 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US14/450,569 Abandoned US20140341991A1 (en) 2007-05-03 2014-08-04 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US14/851,497 Abandoned US20160031822A1 (en) 2007-05-03 2015-09-11 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/073,708 Abandoned US20160199353A1 (en) 2007-05-03 2016-03-18 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/343,382 Abandoned US20170112771A1 (en) 2007-05-03 2016-11-04 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/638,693 Abandoned US20170296512A1 (en) 2007-05-03 2017-06-30 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US15/852,090 Abandoned US20180117009A1 (en) 2007-05-03 2017-12-22 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US16/054,451 Abandoned US20180338926A1 (en) 2007-05-03 2018-08-03 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US16/356,498 Abandoned US20190209479A1 (en) 2007-05-03 2019-03-18 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)

Country Status (34)

Country Link
US (15) US20100129352A1 (es)
EP (4) EP2152237B1 (es)
JP (7) JP5419866B2 (es)
KR (3) KR101537200B1 (es)
CN (3) CN102688207A (es)
AR (1) AR059656A1 (es)
AU (1) AU2007352608B2 (es)
BR (1) BRPI0721651B8 (es)
CA (1) CA2685831C (es)
CL (1) CL2007002242A1 (es)
CO (1) CO6260058A2 (es)
CR (1) CR11143A (es)
CY (1) CY1117284T1 (es)
DK (1) DK2152237T3 (es)
DO (1) DOP2009000253A (es)
EA (2) EA020883B1 (es)
EC (1) ECSP077628A (es)
ES (1) ES2565179T3 (es)
HK (1) HK1136968A1 (es)
HR (1) HRP20160206T1 (es)
HU (1) HUE027209T2 (es)
IL (3) IL201891A (es)
JO (1) JO3643B1 (es)
MA (1) MA30236B1 (es)
MX (1) MX2009011881A (es)
MY (1) MY158072A (es)
NZ (1) NZ580888A (es)
PE (3) PE20121407A1 (es)
PL (1) PL2152237T3 (es)
PT (1) PT2152237E (es)
SI (1) SI2152237T1 (es)
TW (2) TWI439267B (es)
WO (1) WO2008136843A1 (es)
ZA (1) ZA200907710B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2015029074A3 (en) * 2013-09-02 2015-06-04 Hetero Research Foundation Compositions of eltrombopag
WO2022056346A1 (en) * 2020-09-14 2022-03-17 Actavis Laboratories Fl, Inc. Eltrombopag choline dosage forms

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
WO2010045310A1 (en) * 2008-10-16 2010-04-22 Glaxosmithkline Llc Method of treating thrombocytopenia
CN102448942A (zh) 2009-04-01 2012-05-09 普利瓦赫尔瓦茨卡有限公司 艾曲波帕和艾曲波帕盐的多晶型物及其制备方法
EP3127427B1 (en) * 2009-05-29 2020-01-08 Novartis Ag Methods of administration of thrombopoietin agonist compounds
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20150306099A1 (en) * 2012-11-27 2015-10-29 Glaxosmithkline Llc Combination
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
WO2017042839A1 (en) 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
TW201726129A (zh) * 2016-01-22 2017-08-01 江蘇恆瑞醫藥股份有限公司 一種含有雙環取代吡唑酮偶氮類衍生物或其鹽的藥物組成物及其製備方法
CN106361719A (zh) * 2016-08-25 2017-02-01 浙江万晟药业有限公司 一种艾曲泊帕液体胶囊及其制备方法
CN107913411B (zh) * 2016-10-11 2023-08-25 广东东阳光药业股份有限公司 艾曲泊帕包合物及其制剂和制备方法
WO2018078644A1 (en) * 2016-10-24 2018-05-03 Hetero Labs Limited Orally disintegrating tablets of eltrombopag
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US20180280861A1 (en) * 2017-03-30 2018-10-04 JMAC Resources, Inc. Mixer Truck Water Spray Bar
EP3395331B1 (en) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising eltrombopag olamine
CN107468662A (zh) * 2017-10-10 2017-12-15 甘宜玲 一种治疗消化不良的药物片剂及其制备方法
CN107898784B (zh) * 2017-11-01 2020-09-18 天津国际生物医药联合研究院 艾曲波帕乙醇胺在抗结核分枝杆菌感染中的应用
CN109893503A (zh) * 2017-12-11 2019-06-18 武汉武药科技有限公司 一种艾曲泊帕口服混悬液及其制备方法
EP3409272B1 (en) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
US20210308104A1 (en) * 2018-08-02 2021-10-07 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising eltrombopag olamine
CN110327330A (zh) * 2019-08-08 2019-10-15 上海中医药大学 艾曲波帕在制备抗癌血管生成药物及抗癌药物组合物中的应用
WO2021055820A1 (en) 2019-09-20 2021-03-25 Novartis Ag 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
TR201917244A1 (tr) 2019-11-07 2021-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren kapsül
EP4069204A1 (en) 2019-12-06 2022-10-12 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
WO2021110942A1 (en) 2019-12-06 2021-06-10 Synthon B.V. Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
TR202014694A1 (tr) * 2020-09-16 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
EP4014970A1 (en) 2020-12-21 2022-06-22 Genepharm S.A. A solid oral composition of eltrombopag olamine
WO2022195545A1 (en) 2021-03-18 2022-09-22 Novartis Ag Novel pharmaceutical formulations
WO2022201087A1 (en) 2021-03-25 2022-09-29 Novartis Ag 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
WO2023111187A1 (en) 2021-12-15 2023-06-22 Galenicum Health, S.L.U Pharmaceutical compositions comprising eltrombopag
CN115919789A (zh) * 2022-12-08 2023-04-07 山东新时代药业有限公司 一种艾曲泊帕乙醇胺片及其制备方法

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
US2809963A (en) * 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
US4510149A (en) * 1982-07-05 1985-04-09 Farmitalia Carlo Erba S.P.A. N-Imidazolyl derivatives containing naphthalene or indene nucleus
US4582831A (en) * 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
US4686285A (en) * 1984-02-10 1987-08-11 Sandoz Ltd. Basic azo and non-azo compounds having one or two disubstituted 1,3,5-triazine rings each of which is linked through a bridging radical to the 1-position of a pyrazole ring
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US4948900A (en) * 1987-03-18 1990-08-14 Tanabe Seiyaku Co., Ltd. Benzoxazole derivatives
US5214813A (en) * 1992-05-29 1993-06-01 Gastle Thomas H Patient support device
US5238442A (en) * 1992-06-26 1993-08-24 Townsend Engineering Company Method and means for applying liquid to the interior of a casing on a sausage encasing machine
US5248871A (en) * 1990-06-21 1993-09-28 Sumitomo Electric Industries, Ltd. Automatic gain control circuit
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5532202A (en) * 1993-12-28 1996-07-02 Dai Nippon Printing Co., Ltd. Thermal transfer sheet
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5746821A (en) * 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6280959B1 (en) * 1997-10-31 2001-08-28 Smithkline Beecham Corporation Metal complexes
US20010044474A1 (en) * 1999-12-23 2001-11-22 Curatolo William J. Hydrogel-driven layered drug dosage form
US6436915B1 (en) * 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US20040063764A1 (en) * 2001-01-26 2004-04-01 Hiroshi Takemoto Halogen compounds having thrombopoietin receptor agonism
US20040082626A1 (en) * 2001-01-26 2004-04-29 Hiroshi Takemoto Cyclic compounds exhibiting thrombopoietin receptor agonism
US20060178518A1 (en) * 2002-05-22 2006-08-10 Stephen Moore 3'-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US20080286865A1 (en) * 2005-10-13 2008-11-20 Connie Lynn Erickson-Miller Methods for the Preservation of Platelet Efficacy During Storage
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (es)
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
JPH069382A (ja) 1992-04-17 1994-01-18 Takeda Chem Ind Ltd 安定化された固型製剤およびその製造方法
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
EP1961760A3 (en) 1995-06-07 2008-09-03 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
TW522014B (en) 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) * 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19851389A1 (de) * 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CO5210907A1 (es) 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
AU6023300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
DE60025632T2 (de) 1999-09-10 2006-08-10 Smithkline Beecham Corp. Thrombopoietin-mimetika
EP1223944B1 (en) 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietin mimetics
JP2003513965A (ja) 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
HUP0001417A2 (hu) 2000-04-07 2002-12-28 Sanofi-Synthelabo Gyógyászatilag alkalmazható új sók, eljárás előállításukra és azokat tartalmazó gyógyászati készítmények
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6428871B1 (en) * 2000-05-05 2002-08-06 Michael Cozzolino Method of manufacturing decorative wood products from engineered wood products
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7241783B2 (en) 2000-12-19 2007-07-10 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2004532614A (ja) 2000-12-21 2004-10-28 スミスクライン・ビーチャム・コーポレイション 金属キレート化アゴニストによる細胞膜受容体の活性化の調節
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
CN1671379A (zh) 2001-11-30 2005-09-21 Qlt公司 亚肼基吡唑衍生物和它们作为治疗剂的用途
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
EP1531798B1 (en) * 2002-03-20 2012-06-06 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
AUPS245302A0 (en) 2002-05-21 2002-06-13 Cuskelly, John Ventilation control device
AU2003248630A1 (en) 2002-06-06 2003-12-22 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2003297925A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
BRPI0517088A (pt) * 2004-11-17 2008-09-30 Biomarin Pharm Inc formulação de comprimido estável
JP4226002B2 (ja) 2005-12-27 2009-02-18 ルビコン株式会社 積層形フィルムコンデンサの製造方法
US20080055395A1 (en) 2006-08-29 2008-03-06 Motorola, Inc. Creating a dynamic group call through similarity between images
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
GB0719235D0 (en) 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
US2809963A (en) * 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
US4510149A (en) * 1982-07-05 1985-04-09 Farmitalia Carlo Erba S.P.A. N-Imidazolyl derivatives containing naphthalene or indene nucleus
US4686285A (en) * 1984-02-10 1987-08-11 Sandoz Ltd. Basic azo and non-azo compounds having one or two disubstituted 1,3,5-triazine rings each of which is linked through a bridging radical to the 1-position of a pyrazole ring
US4582831A (en) * 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
US4948900A (en) * 1987-03-18 1990-08-14 Tanabe Seiyaku Co., Ltd. Benzoxazole derivatives
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5248871A (en) * 1990-06-21 1993-09-28 Sumitomo Electric Industries, Ltd. Automatic gain control circuit
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
US5214813A (en) * 1992-05-29 1993-06-01 Gastle Thomas H Patient support device
US5238442A (en) * 1992-06-26 1993-08-24 Townsend Engineering Company Method and means for applying liquid to the interior of a casing on a sausage encasing machine
US5532202A (en) * 1993-12-28 1996-07-02 Dai Nippon Printing Co., Ltd. Thermal transfer sheet
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) * 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6280959B1 (en) * 1997-10-31 2001-08-28 Smithkline Beecham Corporation Metal complexes
US20010044474A1 (en) * 1999-12-23 2001-11-22 Curatolo William J. Hydrogel-driven layered drug dosage form
US6436915B1 (en) * 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US20030060453A1 (en) * 2000-04-07 2003-03-27 Zaihui Zhang Pyrazole compounds
US20040063764A1 (en) * 2001-01-26 2004-04-01 Hiroshi Takemoto Halogen compounds having thrombopoietin receptor agonism
US20040082626A1 (en) * 2001-01-26 2004-04-29 Hiroshi Takemoto Cyclic compounds exhibiting thrombopoietin receptor agonism
US20060178518A1 (en) * 2002-05-22 2006-08-10 Stephen Moore 3'-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
US20080286865A1 (en) * 2005-10-13 2008-11-20 Connie Lynn Erickson-Miller Methods for the Preservation of Platelet Efficacy During Storage

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2012121958A3 (en) * 2011-03-08 2014-05-01 Glaxosmithkline Llc Combination
WO2015029074A3 (en) * 2013-09-02 2015-06-04 Hetero Research Foundation Compositions of eltrombopag
US9770437B2 (en) 2013-09-02 2017-09-26 Hetero Research Foundation Compositions of eltrombopag
WO2022056346A1 (en) * 2020-09-14 2022-03-17 Actavis Laboratories Fl, Inc. Eltrombopag choline dosage forms

Also Published As

Publication number Publication date
JP2021100968A (ja) 2021-07-08
SI2152237T1 (sl) 2016-04-29
AU2007352608B2 (en) 2011-12-08
JP2023011888A (ja) 2023-01-24
PL2152237T3 (pl) 2016-06-30
US8052995B2 (en) 2011-11-08
MY158072A (en) 2016-08-30
MX2009011881A (es) 2009-12-16
EA020883B1 (ru) 2015-02-27
KR20100020456A (ko) 2010-02-22
CY1117284T1 (el) 2017-04-26
JP6560289B2 (ja) 2019-08-14
EP2152237B1 (en) 2015-12-30
JP5735078B2 (ja) 2015-06-17
CA2685831A1 (en) 2008-11-13
MA30236B1 (fr) 2009-03-02
DOP2009000253A (es) 2009-12-15
JP2010526140A (ja) 2010-07-29
BRPI0721651A8 (pt) 2017-09-19
AR059656A1 (es) 2008-04-23
EP3090730B1 (en) 2024-04-10
HK1136968A1 (en) 2010-07-16
US8062665B2 (en) 2011-11-22
KR101475971B1 (ko) 2014-12-23
US8071129B2 (en) 2011-12-06
IL238840A0 (en) 2015-06-30
KR101632851B1 (ko) 2016-06-22
EP2152237A1 (en) 2010-02-17
EP2152237A4 (en) 2012-02-08
IL274602B (en) 2021-10-31
EA200971018A1 (ru) 2010-04-30
US20170112771A1 (en) 2017-04-27
TWI538674B (zh) 2016-06-21
EA201400387A1 (ru) 2014-07-30
BRPI0721651A2 (pt) 2014-04-01
US8828430B2 (en) 2014-09-09
US20180117009A1 (en) 2018-05-03
TW201410240A (zh) 2014-03-16
TWI439267B (zh) 2014-06-01
US20100040684A1 (en) 2010-02-18
IL274602A (en) 2020-06-30
CL2007002242A1 (es) 2008-02-08
EP4218732A1 (en) 2023-08-02
TW200843742A (en) 2008-11-16
ZA200907710B (en) 2014-03-26
BRPI0721651B8 (pt) 2021-05-25
US20170296512A1 (en) 2017-10-19
JP6144713B2 (ja) 2017-06-07
KR20150008513A (ko) 2015-01-22
NZ580888A (en) 2012-03-30
KR101537200B1 (ko) 2015-07-15
US20100047348A1 (en) 2010-02-25
WO2008136843A1 (en) 2008-11-13
US20100047347A1 (en) 2010-02-25
US20100040683A1 (en) 2010-02-18
JP2017137343A (ja) 2017-08-10
BRPI0721651B1 (pt) 2019-10-29
JP2019123747A (ja) 2019-07-25
CN102688207A (zh) 2012-09-26
US20120093927A1 (en) 2012-04-19
CN102697745A (zh) 2012-10-03
US8052993B2 (en) 2011-11-08
HRP20160206T1 (hr) 2016-04-08
HUE027209T2 (en) 2016-10-28
JP5419866B2 (ja) 2014-02-19
CO6260058A2 (es) 2011-03-22
PE20151953A1 (es) 2016-01-14
EP4218733A1 (en) 2023-08-02
PE20080773A1 (es) 2008-08-23
AU2007352608A1 (en) 2008-11-13
IL201891A (en) 2016-02-29
US20140341991A1 (en) 2014-11-20
KR20140049086A (ko) 2014-04-24
JO3643B1 (ar) 2020-08-27
IL238840B (en) 2020-05-31
CN101686930A (zh) 2010-03-31
US20180338926A1 (en) 2018-11-29
US20160199353A1 (en) 2016-07-14
US20100047346A1 (en) 2010-02-25
ECSP077628A (es) 2008-12-30
EA034294B1 (ru) 2020-01-27
CA2685831C (en) 2013-11-26
IL201891A0 (en) 2010-06-16
EP3090730A1 (en) 2016-11-09
ES2565179T3 (es) 2016-04-01
US8052994B2 (en) 2011-11-08
JP2015129195A (ja) 2015-07-16
DK2152237T3 (en) 2016-03-14
PT2152237E (pt) 2016-03-28
US20160031822A1 (en) 2016-02-04
PE20121407A1 (es) 2012-11-15
CR11143A (es) 2010-03-22
US20190209479A1 (en) 2019-07-11
JP2014005302A (ja) 2014-01-16

Similar Documents

Publication Publication Date Title
US20190209479A1 (en) 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
AU2016202063B2 (en) Novel pharmaceutical composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BEECHAM CORPORATION, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MULLER, FRANCIS X;KAPSI, SHIVAKUMAR G.;REEL/FRAME:023446/0572

Effective date: 20070801

AS Assignment

Owner name: GLAXOSMITHKLINE LLC, PENNSYLVANIA

Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE BEECHAM CORPORATION;REEL/FRAME:023971/0972

Effective date: 20091027

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION